Evidence-Based Supplement & Herb Guides

p53 Test for Endometrial Cancer: Tumor Subtype, Abnormal Staining, and Prognosis

Learn how p53 IHC classifies endometrial cancer, what wild-type, overexpression, null, and cytoplasmic patterns mean, and why p53-abnormal tumors carry higher risk on average.

The p53 test for endometrial cancer is usually an immunohistochemistry (IHC) stain performed on tumor tissue to help classify the cancer’s molecular subtype. p53...

POLE Mutation Test for Endometrial Cancer: Molecular Subtype, Prognosis, and Mutation Meaning

Learn how POLE mutation testing classifies endometrial cancer, which exonuclease-domain variants matter, and what POLE-mutated results mean for prognosis and treatment.

A POLE mutation test for endometrial cancer looks for specific pathogenic changes in the exonuclease, or proofreading, domain of the POLE gene. When a...

RAD51C and RAD51D Test for Ovarian Cancer: Hereditary Risk, DNA Repair, and Variant Meaning

Learn what RAD51C and RAD51D ovarian cancer genetic tests mean, including hereditary risk, pathogenic variants, VUS results, preventive surgery, HRD biology, and family testing.

A RAD51C and RAD51D test looks for inherited or tumor-acquired changes in two genes that help repair double-strand DNA breaks through homologous recombination. Pathogenic...

ROMA Test for Ovarian Cancer Risk: CA-125, HE4, Menopause Status, and Risk Score

Learn how the ROMA ovarian cancer risk test combines CA-125, HE4, and menopause status, why cutoffs vary by assay, and what high or low risk scores mean before surgery.

The ROMA test, short for Risk of Ovarian Malignancy Algorithm, combines two blood biomarkers—CA-125 and HE4—with menopause status to estimate whether an adnexal mass...

Vulvar Cancer Biomarker Panel: HPV, p16, p53, and Tumor Classification

Learn how HPV, p16, and p53 classify vulvar squamous cell carcinoma, what block-positive and p53-abnormal patterns mean, and why tumor pathway affects prognosis and follow-up.

A vulvar cancer biomarker panel commonly uses HPV testing, p16 immunohistochemistry, and p53 immunohistochemistry to classify vulvar squamous cell carcinoma (VSCC) by its underlying...

ALK Fusion Test for Lung Cancer: Gene Fusion, Positive Result, and Molecular Meaning

Understand ALK fusion testing in lung cancer, including what a positive or negative result means, tissue and ctDNA methods, limitations, and treatment relevance.

An ALK fusion test looks for a specific tumor alteration that can help define the biology of non-small cell lung cancer (NSCLC) and, in...

BRAF V600E Test for Lung Cancer: Mutation Status, Positive Result, and Molecular Meaning

Understand BRAF V600E testing in lung cancer, including what a positive or negative result means, tissue and ctDNA methods, limitations, and treatment relevance.

A BRAF V600E test looks for a specific tumor alteration that can help define the biology of non-small cell lung cancer (NSCLC) and, in...

CEA Test for Lung Cancer: Tumor Marker Monitoring, High Levels, and Result Meaning

Learn how the carcinoembryonic antigen (CEA) test is used in lung cancer, what high levels can mean, common non-cancer causes, reference ranges, and why serial trends matter.

The carcinoembryonic antigen (CEA) blood test can provide supportive information when a person already has lung cancer, especially when the marker is elevated before...

CYFRA 21-1 Test for Lung Cancer: Tumor Marker Levels and Disease Monitoring

Learn how the cytokeratin 19 fragment 21-1 (CYFRA 21-1) test is used in lung cancer, what high levels can mean, common non-cancer causes, reference ranges, and why serial trends matter.

The cytokeratin 19 fragment 21-1 (CYFRA 21-1) blood test can provide supportive information when a person already has lung cancer, especially when the marker...

EGFR Exon 20 Insertion Test: Lung Cancer Mutation Status and Molecular Meaning

Understand EGFR exon 20 insertion testing in lung cancer, including what a positive or negative result means, tissue and ctDNA methods, limitations, and treatment relevance.

An EGFR exon 20 insertion test looks for a specific tumor alteration that can help define the biology of non-small cell lung cancer (NSCLC)...

EGFR Mutation Test for Lung Cancer: Exon 19, L858R, T790M, Mutation Status, and Meaning

Understand EGFR mutation testing in lung cancer, including what a positive or negative result means, tissue and ctDNA methods, limitations, and treatment relevance.

An EGFR mutation test looks for a specific tumor alteration that can help define the biology of non-small cell lung cancer (NSCLC) and, in...

EGFR T790M Test: Lung Cancer Resistance Mutation, ctDNA, and Result Meaning

Understand EGFR T790M testing in lung cancer, including what a positive or negative result means, tissue and ctDNA methods, limitations, and treatment relevance.

An EGFR T790M test looks for a specific tumor alteration that can help define the biology of non-small cell lung cancer (NSCLC) and, in...

HER2/ERBB2 Mutation Test for Lung Cancer: Mutation Status and HER2 Alteration Meaning

Understand HER2/ERBB2 mutation testing in lung cancer, including what a positive or negative result means, tissue and ctDNA methods, limitations, and treatment relevance.

A HER2/ERBB2 mutation test looks for a specific tumor alteration that can help define the biology of non-small cell lung cancer (NSCLC) and, in...

KRAS G12C Test for Lung Cancer: Mutation Status, Positive Result, and Molecular Meaning

Understand KRAS G12C testing in lung cancer, including what a positive or negative result means, tissue and ctDNA methods, limitations, and treatment relevance.

A KRAS G12C test looks for a specific tumor alteration that can help define the biology of non-small cell lung cancer (NSCLC) and, in...

Lung Cancer Biomarker Panel: EGFR, ALK, ROS1, BRAF, MET, RET, NTRK, PD-L1, and Tumor Profile

A lung cancer biomarker panel looks for molecular and protein features that can define the tumor more precisely than histology alone. In non-small cell...

Lung Cancer Liquid Biopsy Test: ctDNA, Mutations, Resistance Markers, and Blood-Based Testing

Learn how lung cancer liquid biopsy uses ctDNA to detect actionable mutations and resistance markers, what positive and negative results mean, and when tissue testing is still needed.

A lung cancer liquid biopsy is a blood-based molecular test that looks for tumor-derived material, most often circulating tumor DNA (ctDNA). It can identify...

Lung Cancer NGS Panel Test: Driver Mutations, Gene Fusions, Resistance Markers, and Molecular Profile

A lung cancer NGS panel is a molecular test that examines many cancer-related genes at the same time. In non-small cell lung cancer (NSCLC),...

Lung Cancer Resistance Mutation Panel: EGFR, ALK, ROS1, MET, and Resistance Markers

Learn how lung cancer resistance mutation panels detect EGFR, ALK, ROS1, MET, and other resistance mechanisms, how blood and tissue testing differ, and what positive or negative results mean.

A lung cancer resistance mutation panel is a molecular test used after targeted therapy stops controlling the cancer or when resistance is strongly suspected....

MET Amplification Test for Lung Cancer: Copy Number Gain, Resistance Marker, and Meaning

Learn how MET amplification testing measures lung cancer copy-number gain, how FISH and NGS results differ, why MET can cause EGFR resistance, and what positive or negative results may mean.

A MET amplification test checks whether lung cancer cells contain extra copies of the MET gene. MET encodes a receptor tyrosine kinase that can...

MET Exon 14 Skipping Test for Lung Cancer: Splice Alteration, Mutation Status, and Meaning

Learn what MET exon 14 skipping means in lung cancer, how DNA and RNA tests detect it, how positive and negative results are interpreted, and why METex14 can guide targeted NSCLC treatment.

A MET exon 14 skipping test looks for a specific oncogenic alteration in the MET gene that causes exon 14 to be removed from...